Technical Brief
Number 1

Particle Beam Radiation Therapies for Cancer
This report is based on research conducted by the Tufts Medical Center Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-07-10055). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
Particle Beam Radiation Therapies for Cancer

Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD  20850
www.ahrq.gov

Contract No. HHSA-290-07-10055

Prepared by:

*Tufts Medical Center Evidence-based Practice Center*

*Investigators*
Thomas A. Trikalinos, M.D., Ph.D.
Teruhiko Terasawa, M.D.
Stanley Ip, M.D.
Gowri Raman, M.D.
Joseph Lau, M.D.
None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the State Children’s Health Insurance Program (SCHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments and Comparative Effectiveness Reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care. Technical Briefs are the most recent addition to this body of knowledge.

A Technical Brief provides an overview of key issues related to a clinical intervention or health care service—for example, current indications for the intervention, relevant patient population and subgroups of interest, outcomes measured, and contextual factors that may affect decisions regarding the intervention. Technical Briefs generally focus on interventions for which there are limited published data and too few completed protocol-driven studies to support definitive conclusions. The emphasis, therefore, is on providing an early objective description of the state of science, a potential framework for assessing the applications and implications of the new interventions, a summary of ongoing research, and information on future research needs.

Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an e-mail list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly, while Technical Briefs will serve to inform new research development efforts.

Carolyn M. Clancy, M.D.  
Director  
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.  
Director, Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality
EPC Program Director

Joseph Lau, M.D.
Tufts Medical Center

AHRQ Contacts

Beth A. Collins Sharp, Ph.D., R.N.
Director
Evidence-based Practice Center Program
Agency for Healthcare Research and Quality
Rockville, MD

Artyom Sedrakyan, M.D., Ph.D.
Task Order Officer
Evidence-based Practice Center Program
Agency for Healthcare Research and Quality
Rockville, MD

Elise Berliner, Ph.D.
Task Order Officer
Evidence-based Practice Center Program
Agency for Healthcare Research and Quality
Rockville, MD
## Contents

Executive Summary .........................................................................................................................ES-1  
Introduction ...................................................................................................................................1  
  Photon Beam Radiotherapy ..............................................................................................1  
  Charged Particle Beam Radiotherapy ...............................................................................1  
Statement of Work ............................................................................................................3  
Methods.........................................................................................................................................5  
  Terminology, Definitions, and Conventions .....................................................................5  
  Gray Literature Searches...................................................................................................6  
  Published Literature Searches ...........................................................................................6  
  Systematic Literature Scan ...............................................................................................6  
Results...........................................................................................................................................9  
  Key Question 1 .................................................................................................................9  
    1.a. What are the different particle beam radiation therapies that have been proposed to be used on cancer? ........................................................................................9  
    1.b. What are the theoretical advantages and disadvantages of these therapies compared to other radiation therapies that are currently used for cancer treatment? ..........................................................................................................................9  
    1.c. What are the potential safety issues and harms of the use of particle beam radiation therapy? ............................................................................................................9  
  Key Question 2 ..............................................................................................................12  
    2.a. What instrumentation is needed for particle beam radiation and what is the FDA status of this instrumentation? .................................................................12  
    2.b. What is an estimate of the number of hospitals that currently have the instrumentation or are planning to build instrumentation for these therapies? ...............15  
    2.c. What instrumentation technologies are in development? ........................................16  
  Key Question 3 ...............................................................................................................17  
    3.a. Types of cancer and patient eligibility criteria .........................................................19  
    3.b. Type of radiation, instrumentation, and algorithms used ........................................22  
    3.c. Study design and size ...............................................................................................23  
    3.d. Comparators .............................................................................................................27  
    3.e. Length of Followup .................................................................................................29  
    3.f. Concurrent or prior treatments ...............................................................................29  
    3.g. Outcomes measured .................................................................................................30  
    3.h. Adverse events, harms, and safety issues reported ..................................................30  
Discussion ...................................................................................................................................33  
  Conclusion ..................................................................................................................................35  
References ...................................................................................................................................37
Figures

Figure 1. Depth-dose distributions for a spread-out Bragg peak of a particle beam for a single entry port.......................................................................................................................................2
Figure 2. Schematic of a proton beam radiotherapy facility.......................................................12
Figure 3. Flow of the literature ...................................................................................................18
Figure 4. All identified studies per center and cancer type........................................................20
Figure 5. Enrollment periods for studies per cancer .................................................................22
Figure 6. Sample sizes of studies per cancer type ......................................................................24
Figure 7. Noncomparative studies per center and cancer type. ..................................................25
Figure 8. Randomized and nonrandomized comparative studies per center and cancer type. ...26
Figure 9. Followup duration per cancer type..............................................................................29

Tables

Table 1. List of treatment planning software/systems for particle beam therapy up to 2002.....14
Table 2. Currently operating particle beam facilities in the US .................................................15
Table 3. Large particle beam facilities that are being built in the US ........................................16
Table 4. Distribution of mean or median ages per cancer category excluding 7 studies on pediatric or adolescent populations.............................................................................................21
Table 5. Number of papers per cancer type and study design ....................................................24
Table 6. Comparators assessed in the randomized controlled trials .........................................27
Table 7. Comparators assessed in the nonrandomized comparative studies ..............................28

Appendixes

Appendix A: Selected Internet Links
Appendix B: Ovid Medline Search Strategy
Appendix C: Table of Eligible Studies
Appendix D: Table of Excluded Studies
Appendix E: Table of Screened Case Series and Case Reports
Appendix F: Centers That Perform Particle Beam Treatment (Worldwide)
Appendix G: Summary Table
Executive Summary

Background

Radiotherapy with charged particles can potentially deliver maximal doses while minimizing irradiation of surrounding tissues. It may be more effective or less harmful than other forms of radiotherapy for some cancers. Currently, seven centers in the United States have facilities for particle (proton) irradiation, and at least four are under construction, each costing between $100 and $225 million. The aim of this Technical Brief was to survey the evidence on particle beam radiotherapy.

Methods

We searched MEDLINE from its inception to July 2009 for publications in English, German, French, Italian, and Japanese. We visited Web sites of manufacturers, treatment centers, and professional organizations for relevant information.

Four reviewers identified studies of any design describing clinical outcomes or adverse events with 10 or more cancer patients treated with charged particle radiotherapy. Each of four reviewers extracted study, patient, and treatment characteristics; clinical outcomes; and adverse events for nonoverlapping sets of papers. A different reviewer verified data on comparative studies.

Results

Figure A summarizes study designs, diseases, and outcomes in the 243 eligible papers. Charged particle beam radiotherapy was used alone or in combination with other interventions for both common cancers (e.g., lung, prostate, breast) and uncommon cancers (e.g., skull base tumors, uveal melanomas). Out of 243 papers, 185 were single-arm retrospective studies, and another 35 studies were prospective single-arm trials. The number of included patients ranged from 10 to 2,645 (median 63). Seven studies (3 percent) focused on a pediatric population; most of the remaining studies reported mean or median age above 50 years. The reported followup periods ranged from 5 to 157 months (median, 36 months) for 188 studies that commented on the pertinent data. Thirty-one studies followed patients longer than 5 years. Two studies had mean followup longer than 10 years.

The spectrum of included patients varied depending on the cancer type. For uveal melanoma, for example, particle beam therapy was used for a wide range of melanoma locations (i.e., choroid plexus, ciliary body, or iris) and sizes. For non-small-cell lung cancer and hepatocellular carcinoma, patients who either refused surgery or were ineligible for other types of therapies received charged particle beam radiotherapy. Typically, studies did not provide detailed information on the cancer staging or explicit descriptions of the clinical context--i.e., primary stand-alone or adjuvant therapy to other therapies for newly diagnosed cancer, or salvage therapy after treatment failure to previous therapies.

Most studies reported patient relevant-clinical outcomes: 151 studies (62 percent) described overall survival; 112 studies (46 percent), cancer specific survival; and 210 studies (86 percent), other surrogate outcomes of overall survival. Some studies reported clinical outcomes that are relevant to the quality of life, such as eye retention rates or visual acuity in uveal melanoma or bladder conservation rates in bladder cancer.
Figure A. Current clinical evidence on charged particle radiotherapy

Notes: Each circle represents a study, with size proportional to the logarithm of the total number of participants included in a study. The number in each cell indicates the total number of studies. Each row shows studies addressing one specific cancer category, and the columns show study designs with reported clinical outcomes. The “Other” row includes studies reporting multiple different cancers. The “Other” columns include studies reporting any clinical outcomes other than overall survival or cancer-specific survival (e.g., disease-free survival, progression-free survival, tumor response rate, or quality of life).

Abbreviations: CS=cancer-specific survival; GI=gastrointestinal; OvS=overall survival.

Seventy-five percent of studies (188) reported the adverse events. Not all studies adopted established scales to evaluate adverse events. Generally, the harms or complications observed were sustained in structures (extraneous to the tumors) that were unavoidably exposed to the particle beam in the course of treatment. However, it was not clear whether the reported adverse events were exclusively attributable to charged particle radiotherapy or to other cointerventions in the case of multimodality treatment, or whether they also would have occurred with conventional radiation therapy.

Eight randomized and nine nonrandomized comparative studies compared treatments with or without charged particles. The eight randomized trials were reported in 10 publications and enrolled 1,278 patients in total (Table A). Primary outcomes were explicitly stated in only three trials, which also reported a priori sample size calculations. Three trials pertained to prostate cancer, whereas the remaining dealt with less common cancers (ocular melanoma, skull base and brain tumors, and pancreatic cancer). All trials enrolled a relatively small sample size, ranging from 15 to 393 patients and studied different comparisons (Table A). Most trials did not
compare charged particle radiotherapy with contemporary alternates. No trial reported significant differences in overall or cancer-specific survival or in total serious adverse events.

Table A. Comparators assessed in the randomized controlled trials

<table>
<thead>
<tr>
<th>Cancer type and center</th>
<th>Comparison</th>
<th>N</th>
<th>Survival (overall/specific)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ocular (uveal melanoma)</strong></td>
<td>Higher vs. lower dose proton RT</td>
<td>188</td>
<td>No/No</td>
</tr>
<tr>
<td>MGH (US)</td>
<td>Higher vs. lower dose proton RT</td>
<td>188</td>
<td>No/No</td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Helium RT vs. I-125 brachytherapy</td>
<td>136; 184</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>CPO (France)</td>
<td>Proton RT vs. proton RT + laser TTT</td>
<td>151</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td><strong>Head/neck (skull base chordoma/chondrosarcoma)</strong></td>
<td>Higher vs. lower dose proton RT</td>
<td>96</td>
<td>Yes/No</td>
</tr>
<tr>
<td>MGH (US)</td>
<td>Higher vs. lower dose proton RT</td>
<td>96</td>
<td>Yes/No</td>
</tr>
<tr>
<td><strong>Head/neck (brain glioblastoma)</strong></td>
<td>Higher vs. lower dose proton RT</td>
<td>15</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Higher vs. lower dose proton RT</td>
<td>15</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td><strong>GI (pancreatic cancer)</strong></td>
<td>Helium RT vs. photon RT</td>
<td>49</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Helium RT vs. photon RT</td>
<td>49</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td><strong>Prostate</strong></td>
<td>Photon RT + standard-dose proton vs. photon RT + high-dose proton</td>
<td>393</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>MGH and LLU (US)</td>
<td>Photon RT + standard-dose proton vs. photon RT + high-dose proton</td>
<td>393</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>MGH (US)</td>
<td>Photon RT + local photon boost vs. photon RT + local proton boost</td>
<td>202; 191</td>
<td>Yes/Yes</td>
</tr>
</tbody>
</table>

**Abbreviations:** CPO=Centre de protonthérapie d'Orsay; GI=gastrointestinal; LLU=Loma Linda University; MGH=Massachusetts General Hospital; N=number of enrolled patients; RT=radiotherapy; TTT=transpupillary thermotherapy; UCSF=University of California San Francisco.

Nine nonrandomized comparative studies were reported in 13 papers (estimated 4,086 unique patients). Comparators assessed in the nonrandomized comparative studies are shown in Table B. Charged particle radiotherapy was compared with: brachytherapy for uveal melanoma (four studies); conventional photon radiation for other cancers (six studies); surgery (three studies). None of the studies used advanced statistical analyses, such as propensity score matching or instrumental variable regressions, to better adjust for confounding. Overall, no study found that charged particle radiotherapy is significantly better than alternative treatments with respect to patient-relevant clinical outcomes.
### Table B. Comparators assessed in the nonrandomized comparative studies

<table>
<thead>
<tr>
<th>Cancer type and center</th>
<th>Comparison</th>
<th>N</th>
<th>Survival (overall/specific)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ocular (uveal melanoma)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPO (France)</td>
<td>Proton RT vs. I-125 brachytherapy</td>
<td>1272</td>
<td>Yes/No</td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Helium RT vs. I-125 brachytherapy</td>
<td>766</td>
<td>No/No</td>
</tr>
<tr>
<td>MGH (US)</td>
<td>Proton RT vs. enucleation</td>
<td>556</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Helium RT vs. I-125 brachytherapy</td>
<td>426</td>
<td>No/No</td>
</tr>
<tr>
<td>CCO (UK)</td>
<td>Proton RT vs. I-125 brachytherapy vs. Ru-106 brachytherapy</td>
<td>267</td>
<td>Yes/No</td>
</tr>
<tr>
<td>MGH (US)</td>
<td>Proton RT vs. enucleation</td>
<td>120</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Proton RT vs. proton RT + laser TTT</td>
<td>56</td>
<td>No/No</td>
</tr>
<tr>
<td><strong>Head/neck (skull base adenocystic carcinoma)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSI (Germany)</td>
<td>SFRT/IMRT vs. SFRT/IMRT + carbon (ion) boost</td>
<td>63</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td><strong>Uterus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIRS (Japan)</td>
<td>Carbon RT vs. photon RT + brachytherapy</td>
<td>49</td>
<td>No/No</td>
</tr>
<tr>
<td><strong>GI (Bile duct)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Proton RT vs. photon RT</td>
<td>62</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>UCSF (US)</td>
<td>Surgery + photon RT vs. surgery + proton RT</td>
<td>22</td>
<td>No/No</td>
</tr>
<tr>
<td><strong>Prostate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LLU (US)</td>
<td>Watchful waiting vs. surgery vs. Stand-alone photon RT vs. photon RT + proton boost RT vs. Stand-alone proton RT</td>
<td>185</td>
<td>No/No</td>
</tr>
<tr>
<td>MGH (US)</td>
<td>photon RT + photon boost vs. photon RT + proton boost</td>
<td>180</td>
<td>Yes/Yes</td>
</tr>
</tbody>
</table>

**Abbreviations:** CCO=Clatterbridge Centre for Oncology; CPO=Centre de protonthérapie d'Orsay; GI=gastrointestinal; GSI=Gesellschaft fuer; IMRT=intensity-modulated radiotherapy; LLU=Loma Linda University; MGH=Massachusetts General Hospital; N=number of included patients; NIRS=National Institute of Radiological Sciences; RT=radiotherapy; SFRT=stereotactic fractionated radiotherapy; TTT=transpupillary thermotherapy; UCSF=University of California San Francisco.

### Remaining Issues and Future Research

In summary, a large number of scientific papers on charged particle radiotherapy for the treatment of cancer currently exist. However, these studies do not document the circumstances in contemporary treatment strategies in which radiotherapy with charged particles is superior to other modalities. Comparative studies in general, and randomized trials in particular (when feasible), are needed to document the theoretical advantages of charged particle radiotherapy to specific clinical situations.

This Technical Brief did not intend to assess outcomes or evaluate the validity of claims on the safety and effectiveness of particle beam radiotherapy. Such questions need to be addressed in comparative studies.

The available slots for particle beam radiotherapy are very limited, and this may have impacted the design of studies conducted to date. Most eligible studies were noncomparative in nature and had small sample sizes.

It is likely that focused systematic reviews will not be able to provide a definitive answer on the effectiveness and safety of charged particle beam radiotherapies compared with alternative interventions. This is simply because of the relative lack of comparative studies in general, and randomized trials in particular.
Comparative studies (preferably randomized) are likely necessary to provide meaningful answers on the relative safety and effectiveness of particle beam therapy vs. other treatment options in the context of current clinical practice. This is especially true for the treatment of common cancers.

Charged particle radiotherapy can deliver radiation doses with high precision anywhere in the patient’s body, while sparing healthy tissues that are not in its entry path. This can be a very important advantage for specific tumors that are anatomically adjacent to critical structures. However, it is very likely that, as this technology becomes increasingly available (and as the associated costs decrease), it will also be increasingly used with much broader indications. This anticipated diffusion of the technology can have important implications (economic, regarding prioritization of resources, and potentially on health outcomes). Especially for many common cancers, such as breast, prostate, lung, and pancreatic cancers, it is essential that the theorized advantages of particle beam therapy vs. contemporary alternative interventions are proven in controlled clinical trials, along with concomitant economic evaluations.
Introduction

Photon Beam Radiotherapy

Most types of cancer radiotherapy use ionizing photon (X-ray or gamma-ray) beams for the local or regional treatment of disease. Ionizing radiation damages the DNA of tumor and healthy cells alike, triggering complex biochemical reactions and eventually resulting in prolonged abnormal cell function and cellular death. Cellular damage increases with \textit{(absorbed) radiation dose} (measured in Gray units, Gy) – the amount of energy that ionizing radiation deposits to a volume of tissue.

Ionizing radiation is harmful to all tissues, malignant or healthy. In clinical practice, lethal tumor doses are not always achievable because of radiation-induced morbidity to normal tissues.\textsuperscript{1} Radiation therapists aim to maximize dose (and damage) to the target tumor and minimize radiation-induced morbidity to adjacent healthy tissues. This is generally achieved by \textit{targeting the beam} to the tumor area through paths that spare nearby critical and radiosensitive anatomic structures; \textit{selecting multiple fields} that cross in the tumor area through different paths, to avoid overexposing the same healthy tissues (as would be done by using a single field); and by \textit{partitioning the total dose in fractions} (small amounts) over successive sessions. Because healthy tissues recover better and faster than malignant ones, with each radiotherapy session the accumulated cellular damage in the targeted tumor increases, while normal tissues are given the opportunity to repair.

Appropriate targeting of the beam is particularly important for tumors that are anatomically adjacent to critical body structures. To date, advances in imaging and radiation treatment planning technologies allow much more precise targeting of radiation therapy, compared to earlier years.\textsuperscript{1} Apart from conventional external radiation therapy, several modalities have been developed that for radiotherapy delivery. The most advanced method for the delivery of high radiation doses with photon beams is intensity modulated radiation therapy (IMRT). IMRT delivers conformal radiation to the target tumor, by “crossing” multiple properly shaped beams of various intensities through paths that spare radiosensitive and critical adjacent tissues.\textsuperscript{2} (The intensity of the beam expresses how many photons traverse a given area of tissue at a unit time.) IMRT and other radiotherapy delivery methods (i.e., conventional radiotherapy, stereotactic radiosurgery with photons and brachytherapy) are further discussed in the Results section of this Technical Brief.

Charged Particle Beam Radiotherapy

An alternative treatment modality is charged particle radiotherapy, which uses beams of protons or other charged particles such as helium, carbon or other ions instead of photons.\textsuperscript{1} As illustrated in \textbf{Figure 1}, charged particles have different depth-dose distributions compared to photons. They deposit most of their energy in the last final millimeters of their trajectory (when their speed slows). This results in a sharp and localized peak of dose, known as the Bragg peak.

The initial energy (speed) of the charged particles determines \textit{how deep} in the body the Bragg peak will form. The intensity of the beam determines \textit{the dose} that will be deposited to the tissues. By adjusting the energy of the charged particles and by adjusting the intensity of the beam one can deliver prespecified doses anywhere in the patient’s body with high precision. To
irradiate a whole tumor area, multiple Bragg peaks of different energies and intensities are combined (Figure 1).

**Figure 1. Depth-dose distributions for a spread-out Bragg peak of a particle beam for a single entry port**

The red line illustrates the dose distribution of a spread-out Bragg peak (SOBP) of a particle beam. The SOBP dose distribution is created by adding the contributions of the 12 “pristine” Bragg peaks (blue lines). The black curve is the depth-dose distribution of a 10 MV photon beam. The horizontal dashed black lines denote the clinically acceptable variation in the plateau dose of the SOBP (±2%). The horizontal green dashed-dot line corresponds to a dose of 90% of the plateau dose of the SOBP, and defines the modulation width. The modulation width can be changed by varying the number and intensity of the pristine Bragg peaks that are added. Note that there is no dose beyond the distal end of the SOBP at approximately 150 mm of depth, and that smaller dose is delivered to the entrance tissues compared to the SOBP. In contrast, the photon beam delivers maximum dose to the entry tissues, as well as substantial dose beyond 150 mm of depth.

Figure and parts of the legend adopted from Levin 2005. 
[Reproduced with permission from Levin et al. Br J Cancer 2005;93:849-54.]

As with photon therapy, the biological effects of charged particle beams increase with (absorbed) radiation dose. Because charged particles interact with tissues in different ways than photons, the same amount of radiation can have more pronounced biologic effects (result in greater cellular damage) when delivered as charged particles. The **relative biological effectiveness** (RBE) is the ratio of the dose required to produce a specific biological effect with Co-60 photons (reference radiation), to the charged particle dose that is required to achieve the same biological effect. The (general) RBE of protons is approximately 1.1. Heavier particles can have different RBE and dose distribution characteristics. For example, carbon ions were reported to have an RBE around 3 in several tissues and experiments.

Because of these physical characteristics of the charged particle beams it is possible to cover the tumor area (in lateral dimensions and depth) using a single radiation field (something that is not possible with photon beams). In general, a set of charged particle fields achieves dose reduction to uninvolved normal tissues, compared to photon radiotherapy. In practice, more than one entry port may be required with charged particles, especially when it is important to achieve adequate skin sparing. We discuss advantages and the disadvantages of charged particle therapy.
and other radiotherapy options (e.g., external radiotherapy with photons and brachytherapy) in a specific section in this Technical Brief.

Ongoing research explores even more advanced methods to deliver charged particle beam radiotherapy. For example, intensity modulated proton therapy, or IMPT, is a methodology that uses a narrow proton beam (a “pencil” beam) that is “scanned” over the target volume by means of a magnetic field, while both the energy (speed) of the protons and the intensity of the beam are modulated. As of this writing, only the Paul Scherrer Institute (PSI) in Switzerland has facilities that deliver IMPT.

**Statement of Work**

The Agency for Healthcare Research and Quality (AHRQ) requested a Technical Brief on the role of particle beam radiotherapy for the treatment of cancer conditions. More specifically, the following key questions were defined by AHRQ after discussions with the Tufts Medical Center EPC:

**Key Questions**

**Key question 1:**
1.a. What are the different particle beam radiation therapies that have been proposed to be used on cancer?
1.b. What are the theoretical advantages and disadvantages of these therapies compared to other radiation therapies that are currently used for cancer treatment?
1.c. What are the potential safety issues and harms of the use of particle beam radiation therapy?

**Key question 2:**
2.a. What instrumentation is needed for particle beam radiation and what is the Food and Drug Administration (FDA) status of this instrumentation?
2.b. What is an estimate of the number of hospitals that currently have the instrumentation or are planning to build instrumentation for these therapies in the US?
2.c. What instrumentation technologies are in development?

**Key question 3:**
Perform a systematic literature scan on studies on the use and safety of these therapies in cancer, with a synthesis of the following variables:

3.a. Type of cancer and patient eligibility criteria
3.b. Type of radiation, instrumentation and algorithms used
3.c. Study design and size
3.d. Comparator used in comparative studies.
3.e. Length of followup
3.f. Concurrent or prior treatments
3.g. Outcomes measured
3.h. Adverse events, harms and safety issues reported
Methods

This Technical Brief has three key questions, as described in the Statement of Work. Key questions 1 and 2 are addressed using information from gray literature searches and narrative review articles. Key question 3 is addressed with a systematic scan of the published medical literature.

Terminology, Definitions, and Conventions

(Charged) Particle Beam Radiotherapy

This includes external radiotherapy that uses protons, helium, carbon, neon, silicon ions or other charged particles. External radiotherapy with electrons, neutrons or $\pi$-mesons is not discussed in this Technical Brief.

Cancer

The operational definition of cancer includes histologically malignant tumors. All other entities or diseases are not considered as “cancer” in this Technical Brief. Examples of other conditions are arteriovenous malformations, benign meningiomas, benign schwannomas, craniopharyngioma, or age-related macular degeneration.

(Absorbed) Radiation Dose

The amount of energy deposited in a given volume of tissue. It is measured in Gray (Gy).

Relative Biological Effectiveness

RBE is the ratio of the dose of (typically) Co-60 photon radiation that will produce a specified biological effect, to the dose of charged particle radiation required to produce the same effect. Exact RBE values can differ across tissues or with particle energy and/or depth (in the patient’s body).

Biologically Effective Dose

The biological effects of a given radiation dose depend on many factors, including type of radiation (photons vs. charged particles), energy of radiation and the composition of the tissue. The biologically effective dose is a concept that incorporates the aforementioned factors, and correlates better with biological effects compared to radiation dose. Generally speaking, it is related to the (absorbed) radiation dose by the following formula:

$$\text{Biologically effective dose} = \text{RBE} \times \text{radiation dose}$$

and is measured in (typically Co-60) Gray equivalents, or GyE.

End-of-Page Footnotes Vs. References

To distinguish Internet and gray literature sources from journal references we follow the convention of listing the former in the bottom of each page using lowercase latin numerals.
Gray Literature Searches

We searched the Internet using the following algorithm. We first searched Google for “particle beam therapy” and “proton beam therapy”, and visited links we considered relevant among those in the first 10 pages of returned results. We visited links hosted in relevant websites or news items and identified the webpages of radiotherapy organizations, institutions that perform particle beam therapy around the world, and companies that develop particle beam therapy instrumentation and treatment planning software.

We also searched the FDA Center for Devices and Radiological Health (CDRH) database to identify particle beam therapy instrumentation that has received FDA clearance (we used the FDA product code “LHN” to identify relevant instrumentation). Finally, we queried the FDA Manufacturer and User Facility Device Experience (MAUDE) database for any reported harms with particle beam therapy instrumentation.

Selected websites and the corresponding links are provided in Appendix A. All listed links in this Technical Brief were active on 10/29/2008.

Published Literature Searches

We performed Ovid MEDLINE searches from 1950 onwards (last search 02/12/2008) using terms such as “proton”, “charged particle”, “helium ion” etc., along with text and MeSH terms for cancer. The complete search strategy is described in Appendix B. We limited searches to human subjects, but we did not set any language or geographical restrictions. We did not use methodological filters to select specific study designs. We updated the aforementioned search to identify additional comparative studies on 07/11/2009. No additional comparative studies were found.

Systematic Literature Scan

Study Eligibility

Four reviewers screened citations at the abstract level to identify potentially relevant studies. All potentially eligible citations were retrieved in full text and were examined for eligibility. We included studies of any design describing particle beam radiotherapy in at least 10 patients with cancer, and reporting any clinical outcome (e.g., death, local tumor control, change in symptoms) or any harm (irrespective of whether it was attributed to particle beam radiotherapy or not). We included studies irrespective of the role of particle beam therapy in the patient management strategy (e.g., sole treatment or in combination with other treatments). We accepted studies published in English, German, French, Italian, and Japanese.

We excluded from the literature scan studies that compared different treatment plans/algorithms, as well as dosimetry-only studies (provided that they did not report any clinical outcomes or harms). We also excluded studies where more that 20% of patients had non-malignant conditions. Case series of less than 10 patients and case reports were not included in the literature scan, but were screened to identify potential harms.
Data Abstraction

We used Epidata version 3.1 to abstract information on the items of interest in electronic forms. The initial version of the data abstraction form was piloted with 15 papers on 5 different types of cancer, and was modified in an iterative process.

We abstracted data on the citation, study design (prospective single arm study, retrospective single arm study, randomized controlled trial [RCT] and nonrandomized comparative study), type of cancer, patient eligibility criteria, study follow up and the period over which patients were treated, as reported in the primary studies. For comparative studies we noted the exact comparisons.

We also recorded the center/facility of particle beam treatment and the number of patients who were treated. We noted the type of particle, total biologically effective dose (in GyE), number of fractions, biologically effective dose per fraction (GyE), and the duration of radiation treatment in weeks. For studies reporting treatment with both particle and photon beams, the aforementioned quantities were extracted in total for both radiotherapy modalities. When the dose per radiation fraction was not reported, it was calculated assuming that all fractions were of equal size. Similarly, whenever total treatment duration was not reported, it was calculated assuming administration of 1 radiation fraction per day, 5 days a week.

We noted information on particle generation and acceleration, beam transportation and the name of treatment planning software or systems (algorithms).

From each study, we gathered information on prior and concurrent treatments (photon radiotherapy, brachytherapy, surgical intervention, chemotherapy, hormonal therapy). We considered “concurrent” all treatments that were administered simultaneously or successively, as long as it could be judged that they were administered as part of a single intervention strategy. “Prior treatments” were the initial failed interventions in patients who were treated for relapse. In practice however, the distinction of prior and concurrent treatments was difficult.

For each study, we recorded whether the following outcomes where reported: overall or cause-specific survival, outcomes related to local tumor control (e.g., [no] local recurrence, complete remission, change in tumor size), outcomes related to distal disease control (metastasis, metastasis free survival), as well as any other clinical outcome, general (e.g., symptomatic relief) or disease-specific (e.g., rate of bladder conservation for bladder cancer).

We also recorded the different harms or adverse events, their timing (acute vs. late) and severity, as reported in the primary studies. Unless otherwise classified in the primary studies, we considered harms that were Grade 3 or higher as “severe”; and harms reported at least 3 months after irradiation as “late”. It should be noted that harms may be incurred by radiation therapy or other treatment interventions, such as chemotherapy or surgery. We recorded the study authors’ opinions on which harms were radiation-induced whenever they were reported; in all other cases we did not attempt to attribute specific harms to different interventions.

Note

It is not the intent of this Technical Brief to assess the outcomes of particle beam therapy for any specific condition.

The literature scan did not abstract numerical data on the rates of clinical outcomes or harms. Most studies were single-arm and comparisons across such studies are subject to confounding and can be misleading. Moreover, many studies refer to overlapping patient populations and are not independent.
Synthesis of Items of Interest

We generated a Summary Table summarizing the 8 items of Key Question 3 (see Statement of Work, items 3.a. to 3.h.) per type of cancer; this is provided in Appendix G. We described the 8 items across all identified papers using graphs and tables, and providing qualitative summaries.

We classified papers according to the different cancer types they described in the following categories:

- Ocular cancer, including mostly uveal melanoma (but also metastasis to the retina and conjunctival cancer)
- Head and neck cancers, including malignancies of the brain (e.g., glioblastoma); of the skull base and of the cervical spine (chordomas and chondrosarcomas), along with other malignancies (e.g., of the sinonasal tract)
- Spinal cancer, including sacral tumors, mainly chordomas and chondrosarcomas
- Gastrointestinal cancers, including liver, esophageal, pancreatic, and bile duct tumors
- Prostate cancer
- Bladder cancer
- Uterine cancer, including uterine cervix and body
- Bone and soft tissue cancers
- Lung cancer (non-small cell)
- Breast cancer
- Miscellaneous (including skin cancer and papers describing a center’s experience with a variety of different cancers)

In addition, specific radiotherapy centers or institutes are no longer active, but were succeeded by another center in the same geographical area (and in the same academic environment). For example, the Harvard Cyclotron Laboratory has been succeeded by the Northeast Proton Therapy Center, and the Lawrence Berkeley Laboratory has been succeeded by the University of California San Francisco proton treatment center. In the presentation of literature scan results, we grouped papers originating from the currently inactive centers along with papers originating from the corresponding centers that succeeded them.

Software

Epidata version 3.1 was used to perform data extraction from eligible papers. Stata/SE version 9 (Stata Corp, College Station, TX) was used for descriptive statistics and graphics.
Results

Key Question 1

1.a. What are the different particle beam radiation therapies that have been proposed to be used on cancer?

1.b. What are the theoretical advantages and disadvantages of these therapies compared to other radiation therapies that are currently used for cancer treatment?

1.c. What are the potential safety issues and harms of the use of particle beam radiation therapy?

1.a. What are the different particle beam radiation therapies that have been proposed to be used on cancer?

As of December 2007 at least 61,800 patients have received particle beam radiotherapy around the world for various cancers and other diseases. The vast majority (approximately 54,000 or 87%) have received protons. Fewer patients have received radiotherapy with carbon ions (approximately 4,500 or 7%), helium ions (approximately 2,000 or 3%) or other ions.\(^i\)

1.b. What are the theoretical advantages and disadvantages of these therapies compared to other radiation therapies that are currently used for cancer treatment?

Particle beams offer the benefit of precise dose localization and have favorable dose-depth distributions, compared with conventional photon beam radiotherapy.\(^6\) It is theorized that this translates to favorable clinical outcomes compared to conventional radiotherapy. Particle beams have a steep increase in energy deposition at the Bragg peak, and deposit very little dose in the normal tissues beyond the Bragg peak location (Figure 1). Therefore, the radiation dose in the normal tissues both at the radiation field entry site and around the target area is less compared to photon radiotherapy.

For these reasons, it is expected that when one uses charged particles rather than photons to deliver a specific biologically effective dose to the tumor area, radiation-induced morbidity from normal tissue damage will be smaller. Conversely, one may have the opportunity to deliver higher (even lethal) doses to the tumor area with charged particles rather than photons, while inducing harms comparable to those seen with photon radiotherapy.\(^6\)

The above is particularly appealing for inoperable tumors located adjacent to critical structures.\(^7\) In the case of uveal melanomas for instance, tumors may develop in close proximity to the optic disk, optic nerve and fovea. Proton beam radiotherapy can deliver therapeutic radiation doses with great precision so as to avoid surgical removal of the eye and preserve vision.\(^6\) Other examples where precise radiation targeting is critical are tumors of the skull base and spine (e.g., sarcomas, chordomas, and chondrosarcomas), that are adjacent to the brain, brain stem, cervical cord, optic chiasm, and spinal cord.\(^1\)

It is theorized that the reduced cumulative dose to normal tissues with particle beam rather than photon radiotherapy is particularly beneficial to pediatric patients.\(^6,8\) This is because

children may be more susceptible to radiation side effects compared to adults.\textsuperscript{8} In addition, a major concern is the potential for secondary radiation-induced malignancies that can appear long after treatment completion. There is evidence that such secondary malignancies increase with total radiation dose.\textsuperscript{8}

We note that, even with charged particle beams, delivery of radiation therapy can be imprecise. Because of the way charged particles interact with matter, dose deposition with charged particle beams is dependent on tissue inhomogeneities (such as air cavities), posing obstacles to the calculation of the exact location of the distal Bragg peak.\textsuperscript{9} Moreover, investigators have described a slight increase in the RBE of charged particles at the distal end of the beam,\textsuperscript{3} which may affect treatment planning.

**Description and Pros and Cons of Radiotherapeutic Alternatives to Particle Beam Therapy**

The following descriptions do not constitute an exhaustive list.

*Conventional photon radiotherapy*

Conventional radiation therapy utilizes ionizing radiation in the form of X-rays generated by linear accelerators, or gamma rays emitted from isotopes such as Co-60. Photon beams deliver the maximum radiation dose just after entering the surface of human body, and gradually wane in energy deposition with penetration depth (Figure 1). Photon radiotherapy results in larger unnecessary radiation dose to normal structures compared to particle beam therapy. Contrary to particle beam therapy, the targeted tumor volume cannot be covered by a single radiation field in depth and lateral dimensions.

However, conventional radiotherapy is widely available and less costly than charged particle radiotherapy. For many patients in whom a whole region has to be irradiated (e.g., the whole pelvis in some patients with uterine cancer), the high precision of particle beam therapy may not be needed. Finally, substantial clinical experience has already accumulated on the biological effects of photons in various tissues and different doses. This is not true in the case of light ions such as carbon ions, (although it is less of an issue with protons).\textsuperscript{10}

*IMRT*

Modern radiotherapy delivery methods capitalize on advances in imaging and radiation treatment planning technologies and allow for much more precise targeting of photon radiotherapy, compared to conventional techniques. The most advanced method for the delivery of high radiation doses with photon beams is IMRT. IMRT delivers conformal radiation to the target tumor, by “crossing” multiple properly shaped radiation fields with various intensities through paths that spare radiosensitive and critical adjacent tissues.\textsuperscript{2,11} IMRT is already used in many hospitals in the US.

A possible concern is that IMRT has a higher integral radiation dose\textsuperscript{1} and increases in the total volume of tissues exposed to radiation compared to conventional radiation therapy. It is theorized that this may translate to higher risk for secondary radiation-induced malignancies, especially in pediatric populations.\textsuperscript{11}

*Stereotactic radiosurgery with photons*

Photon stereotactic radiosurgery uses multiple photon beams of relatively low intensity that converge to the same area, effectively delivering a single, high-dose fraction of external
radiation to a target lesion in the central nervous system. With advances in imaging technologies and immobilization techniques that take better account of tumor motions caused e.g. by respiration, this technique is now possible for cancers located outside the central nervous system. It is now considered one of several approaches to deliver ablative radiation doses directly to the target lesion with acceptable toxicity in adjacent normal tissues.\textsuperscript{12,13}

However, stereotactic radiosurgery with photons is typically not used to irradiate large tumor areas.

**Brachytherapy**

Brachytherapy is another type of radiation therapy where one inserts small encapsulated radioactive sources in or adjacent to the treatment volume. Depending on the type of the source (and the intensity of the radiation) these may be inserted permanently or transiently. The sources emit beta radiation or alpha particles, which deposit all their energy in the immediately neighboring tissue, delivering very little dose to distal tissues. Depending on the type of cancer, the radiation source may be placed adjacent to the tumor (e.g., outside the sclera for some ocular cancers or in the uterus for some gynecologic malignancies), or may be directly implanted in the tumor (e.g., for prostate cancer).\textsuperscript{14}

Brachytherapy has very specific indications. The insertion of the radioactive sources requires minor invasive procedures.

1.c. What are the potential safety issues and harms of the use of particle beam radiation therapy?

Generally speaking, the expected harms from a dose of radiation to a given tissue are considered to be determined by the biologically effective dose, rather than the type of the radiation (photon vs. charged particles).

We found no claims that any harm was specific to the nature of the radiation (i.e., charged particles vs. other types) in the literature we examined. Moreover, we found no mention of non-radiation related harms incurred by the instrumentation used to deliver radiotherapy with charged particles (e.g., injuring a patient during positioning in the treatment room).

In the previous sections we discussed expected benefits and harms stemming from the differential depth-dose distributions of different radiation delivery methods.

**Cautionary Note**

Charged particle radiotherapy is less tolerant than photons of inadequacies in the planning, optimization and execution of radiation therapy. As the delivery of radiotherapy becomes more precise, several issues become more important. First, despite advances in medical imaging, the ability to distinguish tumor tissue from normal tissue is often limited, and this should be accounted for during treatment planning. Second, even when patient immobilization is excellent, one has to compensate for target tissue movements due to respiration, pulse, or peristalsis (e.g., using respiratory gating, widening the treatment volume margins or using other techniques). Third, with repeated treatments, it is important to accurately reproduce the alignment of the beam with the target area, and to account for the shrinkage of the irradiated target tissues as treatment sequence progresses.

Various charged particles (i.e., protons, helium or carbon ions) have different depth-dose distributions. Especially for light ions (such as carbon ions) and less so for protons, RBE values can vary with energy and/or depth. This means that isodoses (in Gy) in a given tissue (tissue
volumes that receive the same radiation dose) do not necessarily correspond to biologically iso-effective doses (in GyE) (tissue volumes that have received the same biologically effective dose).\textsuperscript{10} In addition, the early and late radiosensitivity of various tissues could be different compared to what is known from photon radiotherapy.\textsuperscript{10} Therefore treatment plans generated by different methods for light ions may not result in identical actual doses in a given patient. In contrast to other ions, to date experience with protons suggests that for the same biological dose, the sensitivity of different tissues to protons is the same as with photons.

**Key Question 2**

2.a. What instrumentation is needed for particle beam radiation and what is the FDA status of this instrumentation?

2.b. What is an estimate of the number of hospitals that currently have the instrumentation or are planning to build instrumentation for these therapies?

2.c. What instrumentation technologies are in development?

**2.a. What instrumentation is needed for particle beam radiation and what is the FDA status of this instrumentation?**

**Instrumentation**

*Figure 2* outlines a proton beam radiotherapy facility that has 5 treatment rooms, 1 with a fixed beam and 4 with rotational gantries. This is one of several possible layouts of a particle beam treatment facility.

**Figure 2. Schematic of a proton beam radiotherapy facility**

The following describes the course of a particle beam used for radiotherapy of cancer, from its generation, to the patient room.

1. The charged particles are generated by an ion source. The ion source is specific to the type of the charged particle (i.e., is different for protons, helium ions or carbon ions).
2. The main accelerator is typically a cyclotron, a large device that can accelerate the charged particles to higher energies (typically above 50 MeV). For clinical uses, the maximum
energies that charged particle accelerators achieve are between 230 and 250 MeV (some centers have a maximum clinical energy of 430 MeV see Appendix F, Table F1 for details).

3. The accelerated particle beam is then transported by a series of tubes that are under vacuum and shaping and focusing magnets towards the patient treatment rooms. Special devices (wedges) can decrease particle energy (speed) to desirable levels.

4. The largest facilities in the world have 5 rooms (Appendix F) for treatment administration. In the treatment rooms, the particle beam has either fixed direction (“fixed beam” – horizontal, vertical, or at a specific angle), or can be delivered to any desirable direction by use of rotational gantries. Gantries are large devices that can rotate 360 degrees (full circle) to deliver the particle beam at the angle specified by the radiotherapy team.

5. Finally, the beam delivery nozzle has the ability to shape the beam so that it conforms to the stereometry of the tumor (both the cross-section shape of the tumors and the shape of the distal surface, by using collimators and compensators, respectively).

6. Patients are properly positioned to receive therapy. At least some centers use robotic instrumentation that is able to position patients accurately with 6 degrees of freedom (6 directions of movement or rotation).

7. There is also a therapy control system that provide the interface to control and monitor equipment to deliver treatment to the patient.

The stages outlined above can differ for facilities that use other types of accelerators such as synchrotrons or synchrocyclotrons rather than cyclotrons. For example, synchrotrons offer the ability to control the energy, intensity and even the shape of the beam with electronic means, rather than physical means (wedges), but they deliver the beam in pulses rather than continuously. More detailed discussion of technical information is outside the scope of this Technical Brief.

### Treatment Planning Software/Systems

Several pieces of software were developed for treatment planning since the early 80’s. Table 1 provides a list of treatment planning software/treatment planning systems released up to 2002.¹⁵
Table 1. List of treatment planning software/systems for particle beam therapy up to 2002

<table>
<thead>
<tr>
<th>Year</th>
<th>Created By</th>
<th>Software/system name</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1979–1993</td>
<td>LBL</td>
<td>LBL system</td>
<td>Not available</td>
</tr>
<tr>
<td>1980</td>
<td>MGH</td>
<td>Rx</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>MGH</td>
<td>EYEPLAN</td>
<td>Eyes only</td>
</tr>
<tr>
<td>1990–1996</td>
<td>MGH/Siemens</td>
<td>V-Treat (AXIOM)</td>
<td>Not available</td>
</tr>
<tr>
<td>1987–1991</td>
<td>PSI</td>
<td>PSI system/Pion</td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>DKFZ/Royal Marsden</td>
<td>Voxelplan/Proxelplan</td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>Radionics/MGH</td>
<td>P-Knife</td>
<td>Not available</td>
</tr>
<tr>
<td>1997</td>
<td>LLU/PerMedics</td>
<td>OptiRad 3D</td>
<td>FDA approved, commercial</td>
</tr>
<tr>
<td>1998</td>
<td>Tsukuba</td>
<td>Hitachi system</td>
<td>In-house system</td>
</tr>
<tr>
<td>1998</td>
<td>NCC/SHI</td>
<td>PTplan</td>
<td>In-house system</td>
</tr>
<tr>
<td>1998</td>
<td>DKFZ</td>
<td>OCTOPUS</td>
<td>Under development – eyes only</td>
</tr>
<tr>
<td>1994</td>
<td>Orsay/Curie</td>
<td>ISIS</td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>CMS/MGH</td>
<td>FOCUS</td>
<td>Commercial release 1999</td>
</tr>
<tr>
<td>1998</td>
<td>DKFZ</td>
<td>KonRad Plus Protons</td>
<td>Research only</td>
</tr>
<tr>
<td>1989–2000</td>
<td>Clatterbridge, UK</td>
<td>EYEPLAN v1.6 (VMS)</td>
<td>Free; eyes only; research only</td>
</tr>
<tr>
<td>1999</td>
<td>GSI</td>
<td>TRIp98</td>
<td>Research</td>
</tr>
<tr>
<td>2000</td>
<td>Varian</td>
<td>Polaris</td>
<td>FDA approved for passive treatment modalities</td>
</tr>
<tr>
<td>2001</td>
<td>ITEP (Moscow)</td>
<td>ProGam</td>
<td>Adapted in PTF ITEP</td>
</tr>
<tr>
<td>2002</td>
<td>MDS Nordion</td>
<td>Helax-TMS</td>
<td>FDA approved for commercial use</td>
</tr>
<tr>
<td>2002</td>
<td>CMS/Mitsubishi</td>
<td>FOCUS/M</td>
<td>Commercial release 2001</td>
</tr>
</tbody>
</table>

DKFZ: Deutsches Krebsforshungszentrum; FDA: Food and Drug Administration; GSI: Gesellschaft für Schwerionenforschung; ITEP: Institute of Theoretical and Experimental Physics; LBL: Lawrence Berkeley Laboratory; LLU: Loma Linda University Medical Center; MGH: Massachusetts General Hospital; NCC: National Cancer Center (Japan); PSI: Paul Scherrer Institute.

We repeat the note made in the answer to key question 2.c that—especially for light ions such as carbon ions and less so for protons—RBE values depend on energy and/or depth, complicating treatment planning.10 Because this is an active area of research, treatment plans generated by different methods for light ions may not result in identical actual doses in a given patient.10

**FDA Status of Proton Therapy Equipment**

There are several companies that are undertaking construction of large scale particle treatment instrumentation and facilities. Currently, the FDA has cleared specific devices as substantially equivalent to a medical cyclotron using protons that was in commercial use during the 1960s and 70s. All US facilities that are currently active have FDA cleared instrumentation.ii

**Accreditation and Training**

There is no specific mandatory accreditation for the operation of particle beam facilities. The specialized personnel would have to become proficient with the treatment planning software and in the operation of the patient positioning platforms and the rotational gantries.

Training programs have been ongoing at the Massachusetts General Hospital and at the Loma Linda University for the past few decades. The training covers various aspects of proton therapy.

It is also advertised that, in the US, training programs are slated to be provided at the ProCure Training and Development Center (Bloomington, Indiana), a private center that will simulate a working proton therapy facility. The center is advertised to provide clinical, technical, interpersonal and administrative training for radiation oncologists, medical physicists, dosimetrists, radiation therapists and other staff.

2.b. What is an estimate of the number of hospitals that currently have the instrumentation or are planning to build instrumentation for these therapies?

As of this writing, at least 29 institutes around the world are currently operating facilities for particle beam radiation therapy (Appendix F, Table F1): 7 in Japan, 6 in the US, 3 in Russia, 2 in each of Switzerland, France, and Germany, and 1 in each of England, Canada, Italy, China, Sweden, South Africa and Korea. Table 2 lists the ones that are currently operating in the US.

<table>
<thead>
<tr>
<th>Institute</th>
<th>Particle</th>
<th>Maximum Clinical Energy (MeV)</th>
<th>Beam direction</th>
<th>First patient</th>
<th>Patients treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loma Linda University Medical Center</td>
<td>proton</td>
<td>250</td>
<td>Y – Y</td>
<td>1990</td>
<td>11414 Nov-06</td>
</tr>
<tr>
<td>Midwest Proton Radiotherapy Clinic</td>
<td>proton</td>
<td>200</td>
<td>Y – –</td>
<td>1993</td>
<td>379 Dec-07</td>
</tr>
<tr>
<td>University of California San Francisco</td>
<td>proton</td>
<td>60</td>
<td>Y – –</td>
<td>1994</td>
<td>920 Mar-07</td>
</tr>
<tr>
<td>Northeast Proton Therapy Center-Massachusetts General Hospital</td>
<td>proton</td>
<td>235</td>
<td>Y – Y</td>
<td>2001</td>
<td>2710 Oct-07</td>
</tr>
<tr>
<td>Florida Proton Therapy Institute</td>
<td>proton</td>
<td>230</td>
<td>Y – Y</td>
<td>2006</td>
<td>527 Dec-07</td>
</tr>
<tr>
<td>Procure Proton Therapy Center, OK</td>
<td>proton</td>
<td>[?]</td>
<td>1</td>
<td>2009</td>
<td>NA</td>
</tr>
</tbody>
</table>

Table 2. Currently operating particle beam facilities in the US

FPTI: Florida Proton Therapy Institute; LLU: Loma Linda University Medical Center; NPTC-MGH: Northeast Proton Therapy Center-Massachusetts General Hospital; MRPI: Midwest Proton Radiotherapy Clinic; UCSF: University of California San Francisco.

N: number; NA: not applicable; H: horizontal; V: vertical; Y: yes; Gan: Gantry

Ordered by the time of treatment of the first patient. The table does not include two centers that are now inactive, namely the Lawrence Berkeley Laboratory in California (succeeded by UCSF) and the Harvard Cyclotron Laboratory in Massachusetts (succeeded by NPTC-MGH).


There are at least 3 large facilities that are in construction phase in the US (Table 3). Around the world at least 9 additional particle beam centers have been planned, and 7 of them are in construction phase (4 in Germany, 1 in Switzerland, 1 in Italy and 1 in France; Appendix F, Table F2). As mentioned in the next section, several US hospitals have expressed interest in building smaller scale proton beam facilities.

---

Table 3. Large particle beam facilities that are being built in the US

<table>
<thead>
<tr>
<th>Institute</th>
<th>Now in construction</th>
<th>Particle</th>
<th>Maximum Clinical Energy (MeV)</th>
<th>Treatment rooms</th>
<th>Cost (million $)</th>
<th>Estimated start date</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Pennsylvania, PA</td>
<td>Yes</td>
<td>proton</td>
<td>230</td>
<td>5</td>
<td>4</td>
<td>140</td>
</tr>
<tr>
<td>Hampton University, VA</td>
<td>Yes</td>
<td>proton</td>
<td>[?]</td>
<td>5</td>
<td>4</td>
<td>225</td>
</tr>
<tr>
<td>Northern Illinois Proton Treatment and Research Center, IL</td>
<td>Yes</td>
<td>proton</td>
<td>250</td>
<td>4</td>
<td>2</td>
<td>159</td>
</tr>
</tbody>
</table>

[?] This item could not be found.


See also Appendix F, Table F2 for a list of particle beam therapy centers that are being built around the world.

2.c. What instrumentation technologies are in development?

**Proton Beam Therapy Using Conventional Accelerators (Cyclotron)**

The current particle beam treatment facilities are large and costly (Table 3). Private companies design smaller instrumentation that can fit in a single room and will be able to treat one patient at a time (with protons only – not with other charged particles). According to company websites, the same room will accommodate the cyclotron, the proton beam delivery system, a treatment couch with pendant control, a radiographic patient positioning system, proton beam treatment planning, and a link to a treatment record and verification system. The cost of this newer instrumentation is reported to be 20 million US dollars.

Details on the proprietary technologies that allow the shrinkage of the whole facility to a single room have not been disclosed. However, it is reported that the key technological advancement is the construction of a cyclotron that operates at a very large magnetic field (10 Tesla, using superconducting technology). The cyclotron weighs less than 20 tons, a 90% decrease in weight compared to other proton therapy cyclotrons.

As is the case for larger facilities, the new technology is advertised to include robotic patient positioning system, enabling clinicians to automatically reposition a patient from the control room.

The first such unit will be operated in the Barnes-Jewish Hospital, St Louis, Missouri, in late 2009. This center expects to treat approximately 250 patients each year. According to news items and press releases, several other hospitals have expressed interest in this new instrumentation, including Broward General at Ft. Lauderdale, Orlando Regional at Orlando,

---

iv The information pertains to the Clinatron250™ or Monarch250™ proton beam radiotherapy system, by Still River Systems; the information is accessible at http://www.stillriversystems.com/products.aspx?id=50 (last accessed 10/29/2008).


Florida, vii and Tufts Medical Center, Boston, Massachusetts. At least 17 hospitals have indicated interest in these smaller systems.

The FDA has not yet cleared this new instrumentation.

**Proton Beam Therapy Using Non-Conventional Accelerators (Dielectric Wall Accelerator)**

Other companies have recently announced plans to built small (room size) proton beam therapy facilities using a dielectric wall accelerator instead of a cyclotron. viii

The FDA has not yet cleared this new instrumentation (which is still in early development stage).

**Key Question 3**

Section C describes the results of a systematic scan of the eligible published literature.

**Literature Selection**

Our electronic searches yielded 4747 studies, 470 of which were retrieved in full text (Figure 3). Finally, 243 papers were included in the literature scan. The update search for comparative trials did not identify any additional eligible studies published after the initial search. Appendices C and D list the citations of the retrieved eligible papers and of the excluded papers (along with reasons for exclusion). Appendix E lists the citations of the case reports and case series papers that were examined for harms.

---


The original search is shown on the left. The update search for comparative studies is shown on the right.

* Russian and Dutch
N: number of patients; RT: radiotherapy
3.a. Types of cancer and patient eligibility criteria

Types of Cancer Studied

Particle beam therapy has been used in a variety of cancers in the published literature. More than half of the identified papers described treatment of ocular cancers (uveal melanoma in particular), and cancers of the head and neck (brain tumors, and tumors arising from skull base, cervical spine and nearby structures).

In order of decreasing number of studies, the following types of malignancies were also described: gastrointestinal (esophageal cancer, hepatocellular carcinomas of the liver, pancreatic cancer), prostate, lung, spine and sacrum, bone and soft tissue, uterine (cervix and corpus), bladder, and miscellaneous (skin cancer or a compilation of a center’s experience with a variety of cancers treated there) (Appendix G, Summary Table).

Figure 4 summarizes all identified papers per cancer type and center where the study was conducted. Studies shown in the same cell (i.e., studies from the same center describing a specific cancer) may include overlapping populations. Specific centers appear to have special interest on certain cancer types (Figure 4).
Figure 4. All identified studies per center and cancer type

Each publication is represented by a circle, with size proportional to the logarithm of the total sample size. The red numbers in the right hand corner of each cell denote the total number of studies in each cell.

Shown are all studies that report the center in which the particle beam therapy was performed.
Specific Patient Inclusion and Exclusion Criteria

The vast majority of studies were retrospective cohorts describing the experience of a center in treating several types of cancer. The spectrum of included patients varied depending on the cancer type (Appendix G, Summary Table). For example, particle beam therapy was used in patients with non-small cell lung cancer (most stage I disease) who either refused surgery or had inoperable cancer. For uveal melanoma, particle beam therapy was used for a wide range of melanoma locations and sizes. For bone and soft tissue tumor, patients with either inoperable or metastatic disease were studied. Many studies did not provide information on the cancer staging of the included patients.

Mean or Median Ages

Only 7 papers focused on pediatric or adolescent populations, and they described the treatment of head and neck cancers or of soft tissue sarcomas.\textsuperscript{16-22}

In the remaining papers, mean (or median) ages ranged from 29 to 81 years of age, and many of them described populations with mean age above 50 years (Table 4).

Table 4. Distribution of mean or median ages per cancer category excluding 7 studies on pediatric or adolescent populations

<table>
<thead>
<tr>
<th>Cancer category</th>
<th>Number of identified papers</th>
<th>Mean or median age</th>
<th>Median value</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular</td>
<td>91</td>
<td>58</td>
<td>35-66</td>
<td></td>
</tr>
<tr>
<td>Head/neck</td>
<td>50</td>
<td>49</td>
<td>33-66</td>
<td></td>
</tr>
<tr>
<td>Spine</td>
<td>9</td>
<td>51</td>
<td>41-66</td>
<td></td>
</tr>
<tr>
<td>GI (including liver &amp; pancreas)</td>
<td>21</td>
<td>63.5</td>
<td>59-81</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>19</td>
<td>69</td>
<td>66-73</td>
<td></td>
</tr>
<tr>
<td>Bladder</td>
<td>3</td>
<td>69</td>
<td>55-72</td>
<td></td>
</tr>
<tr>
<td>Uterus</td>
<td>5</td>
<td>60</td>
<td>56-64</td>
<td></td>
</tr>
<tr>
<td>Bone/soft tissue</td>
<td>5</td>
<td>41</td>
<td>29-50</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>17</td>
<td>72</td>
<td>71-75</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>2</td>
<td>62</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>14</td>
<td>68.5</td>
<td>64-73</td>
<td></td>
</tr>
</tbody>
</table>

GI: Gastrointestinal [cancer]; NA: not applicable

Periods of Patient Enrollment

Identified studies reported on patients who were treated from the early 1970’s onwards. Fifty-five percent of the papers reported the centers’ experiences with particle beam therapy over a time span of 10 years or longer.
Figure 5. Enrollment periods for studies per cancer

Ocular (91) -
Head/neck (57) -
Spine (9) -
GI (21) -
Prostate (19) -
Bladder (3) -
Uterus (5) -
Bone/soft tissue (6) -
Lung (17) -
Breast (2) -
Miscellaneous (13) -


Years covered in published studies

GI: Gastrointestinal [cancer]

Shown are enrollment periods of identified studies per cancer classification. Each paper reporting information on coverage periods is represented by a thin horizontal line. Papers are grouped by cancer category and are ordered by calendar year of enrollment start, and total number of studied subjects. The total number of studies per cancer category is shown in the parentheses in the labels of the vertical axis; however, only 204 papers that reported the pertinent information are plotted.

3.b. Type of radiation, instrumentation, and algorithms used

Type of Charged Particle Radiation Used

Proton beam therapy

One hundred twenty-seven papers reported proton beam radiation therapy for various types of cancer. Proton therapy was administered mainly as a single radiation modality, either stand-alone therapy or a part of combined modality therapy (e.g., surgery followed by adjuvant radiotherapy), for ocular melanoma, bone and soft tissue sarcomas, non-small cell lung cancer, hepatocellular carcinoma, and breast cancer. For other cancers, such as malignant tumors in the head, neck, or spine (mainly consisting of chordoma or chondrosarcoma), prostate cancer, bladder cancer, uterine cancer, particle therapy was used either as booster irradiation of the main target lesion on top of conventional photon irradiation, or as the sole treatment.

Administered doses and fractionations thereof were heterogeneous and varied by the type of cancer. Studies administered protons or photon plus protons with mean total dose ranging from 32 to 94 GyE depending on cancer category. When used as booster therapy, proton irradiation was added on top of conventional photon radiotherapy of 40 to 50 Gy. The reported fraction size varied across and within cancer categories, ranging from 2.0 to 5.0 GyE in most instances. Most commonly, the scheduled total activity was fractionated into approximately 20 to 40 doses (one per day) necessitating a one- to two-month treatment period. In some studies where protons where the only radiotherapy (e.g., in non small cell lung cancer and breast cancer) a “hypofractionated” approach was used, with fraction doses in excess of 5.0 GyE, and
approximately 2 weeks’ duration. Most ocular melanoma studies adopted a four or five fraction strategy, which was completed within a week.

**Carbon ion beam therapy**

Thirty-nine publications mainly from two institutions (NIRS, Japan and GIS, Germany) reported use of carbon ion beam therapy. In most cases, carbon ion therapy was used as the only radiation treatment. Treated cancers included malignant tumors in the head, neck and spine, non-small cell lung cancer, prostate cancer, uterine cancer, bone and soft tissue sarcomas, ocular melanoma, and hepatocellular carcinoma.

Most studies administered carbon-ions with mean total dose between 50 and 70 GyE with 15 to 25 treatment fractions during the overall treatment period of one to two months. Lung cancer and ocular melanoma studies used “hypofractionated” approaches with the mean total dose of 70 to 76 GyE administered within a week.

**Helium/Neon/Silicon ion beam therapy**

A single currently inactive facility (University of California, Lawrence Berkeley Laboratory) reported 35 studies on the use of helium, neon or silicon ions from 1982 to 1998. Treated cancer categories were mainly limited to malignant tumors in the head, neck and spine, ocular melanoma (helium ions only), and some gastrointestinal cancers. These ions were used either as a local booster irradiation following conventional photon irradiation or as the only radiation therapy. Most studies administered total doses between 60 to 76 GyE in 30 to 37 fractions during two to three months, except for ocular melanoma studies in which four to five high-dose fractions were administered within 1-2 weeks.

**Details on Instrumentation and Treatment Planning Algorithms**

The identified studies did not provide details on the source of the particles, the accelerator, or the transportation of the beam to the patients (refer to Sections A and B for relevant information).

The description of the treatment planning algorithms (software/method) used by different centers is heterogeneous. Studies mentioned various specific pieces of software (e.g. EYEPLAN for ocular cancer), or alluded to the use of unspecified “treatment planning software” or “treatment planning system.”

**3.c. Study design and size**

We identified 10 RCTs and 13 nonrandomized comparative studies (see Comparators in this section). The remaining 220 studies were single-arm studies (case series or cohort studies); 185/220 were retrospective in design.
Table 5. Number of papers per cancer type and study design

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Single arm</th>
<th>RCTs</th>
<th>Nonrandomized comparative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular</td>
<td>80</td>
<td>4</td>
<td>7</td>
<td>91</td>
</tr>
<tr>
<td>Head/neck</td>
<td>53</td>
<td>2</td>
<td>1</td>
<td>56</td>
</tr>
<tr>
<td>Spine</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>GI</td>
<td>18</td>
<td>1</td>
<td>2</td>
<td>21</td>
</tr>
<tr>
<td>Prostate</td>
<td>14</td>
<td>3</td>
<td>2</td>
<td>19</td>
</tr>
<tr>
<td>Bladder</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Uterus</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Bone/soft tissue</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Lung</td>
<td>17</td>
<td>0</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>Breast</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>14</td>
</tr>
</tbody>
</table>

GI: gastrointestinal [cancers]; RCT: randomized controlled trial

**Figure 6** shows histograms of study sample sizes per cancer category. Overall, 46 studies described more than 300 people. Among them were 1 RCT\(^{33}\) and 4 comparative nonrandomized trials.\(^{34-37}\)

**Figure 6. Sample sizes of studies per cancer type**

![Histograms of study sample sizes per cancer type](image)

GI: Gastrointestinal
The horizontal axis has been transformed to a logarithmic scale to accommodate the large range of total number of included patients per study. The reference lines at 30 and 300 are arbitrarily chosen to facilitate comparisons across the subgraphs per cancer type. The “miscellaneous” category includes studies that reported a center’s cumulative experience on several cancer types, and a study on skin cancer treatment.

**Figure 7** and **Figure 8** show how the identified studies break down into single arm studies, and comparative ones, respectively, per cancer type and center.
Figure 7. Noncomparative studies per center and cancer type

Each publication is represented by a circle, with size proportional to the logarithm of the total sample size. The red numbers in the right hand corner of each cell denote the total number of noncomparative studies.

The relative sizes of the markers are in the same scale with those in Figure 4.

Black circles: Shown are all noncomparative studies that report the center in which the particle beam therapy was performed. For completeness, light gray circles denote comparative studies (their number is not included in the count.)
Each publication is represented by a red circle (randomized trials, RCTs) or a blue square (nonrandomized comparative studies, nonRCT) with size proportional to the logarithm of the total sample size.

The relative sizes of the markers are not in the same scale as in Figure 4 or in Figure 7.

The red and blue numbers in each cell denote the total number of RCTs and non randomized comparative studies, respectively.
3.d. Comparators

In total we identified 10 papers describing 8 RCTs (Table 6) and 13 papers describing nonrandomized comparative studies.34-46

RCTs

The identified RCTs compared lower vs. higher doses of particle beam therapy; particle beam therapy vs. other radiotherapy (e.g., brachytherapy or external photon therapy) or vs. a combination with additional therapy (e.g. laser thermotherapy for uveal melanoma). Table 6 lists the exact comparisons.

Table 6. Comparators assessed in the randomized controlled trials

<table>
<thead>
<tr>
<th>Cancer type and center</th>
<th>Comparison</th>
<th>N</th>
<th>Survival [Overall/ specific]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular (uveal melanoma)</td>
<td>MGH (US)37</td>
<td>Higher vs. lower dose proton RT</td>
<td>188</td>
</tr>
<tr>
<td></td>
<td>UCSF (US)40,41</td>
<td>Helium RT vs. I-125 brachytherapy</td>
<td>136; 184</td>
</tr>
<tr>
<td></td>
<td>Orsay (France)50</td>
<td>Proton RT vs. proton RT + laser TTT</td>
<td>151</td>
</tr>
<tr>
<td>Head/neck (skull base chordoma/chondrosarcoma)</td>
<td>MGH (US)51</td>
<td>Higher vs. lower dose proton RT</td>
<td>96</td>
</tr>
<tr>
<td>Head/neck (brain glioblastoma)</td>
<td>UCSF (US)52</td>
<td>Higher vs. lower dose proton RT</td>
<td>15</td>
</tr>
<tr>
<td>GI (pancreatic cancer)</td>
<td>UCSF (US)53</td>
<td>Helium RT vs. photon RT</td>
<td>49</td>
</tr>
<tr>
<td>Prostate</td>
<td>MGH &amp; LLU (US)33,34</td>
<td>Photon RT + standard dose proton vs. Photon RT + high dose proton</td>
<td>393</td>
</tr>
<tr>
<td></td>
<td>MGH (US)34,35</td>
<td>Photon RT + local photon boost vs. Photon RT + local proton boost</td>
<td>202; 191</td>
</tr>
</tbody>
</table>

GI: Gastrointestinal; RT: radiotherapy; TTT: transpupillary thermotherapy
Nonrandomized Comparative Studies

Table 7 shows the identified 13 nonrandomized comparative studies. Comparators varied according to cancer type. For example, particle beam radiotherapy (as the only treatment) was compared to eye enucleation or brachytherapy in several studies on uveal melanoma. For treatment of other cancers particle beam radiotherapy was typically one of two or more components of the compared patient management strategies.

Table 7. Comparators assessed in the nonrandomized comparative studies

<table>
<thead>
<tr>
<th>Cancer type and center</th>
<th>Comparison</th>
<th>N</th>
<th>Survival [Overall/ specific]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular (uveal melanoma)</td>
<td>Proton RT vs. I-125 brachytherapy</td>
<td>1272</td>
<td>Yes/No</td>
</tr>
<tr>
<td>Orsay (France) (^{30})</td>
<td>Helium RT vs. I-125 brachytherapy</td>
<td>766</td>
<td>No/No</td>
</tr>
<tr>
<td>UCSF (US) (^{30})</td>
<td>Proton RT vs. enucleation</td>
<td>556</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>MGH (US) (^{30})</td>
<td>Helium RT vs. I-125 brachytherapy</td>
<td>426</td>
<td>No/No</td>
</tr>
<tr>
<td>Wilson 1999 - Unclear center (^{30})</td>
<td>Proton RT vs. I-125 brachytherapy vs. Ru-106 brachytherapy</td>
<td>267</td>
<td>Yes/No</td>
</tr>
<tr>
<td>MGH (US) (^{30})</td>
<td>Proton RT vs. enucleation</td>
<td>120</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>UCSF (US) (^{30})</td>
<td>Proton RT vs. proton RT + laser TTT</td>
<td>56</td>
<td>No/No</td>
</tr>
<tr>
<td>Head/neck (skull base adenocystic carcinoma)</td>
<td>SFRT/IMRT vs. SFRT/IMRT + carbon (ion) boost</td>
<td>63</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>GI (Bile duct)</td>
<td>Carbon RT vs. photon RT + brachytherapy</td>
<td>49</td>
<td>No/No</td>
</tr>
<tr>
<td>UCSF (US) (^{30})</td>
<td>Proton RT vs. photon RT</td>
<td>62</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>UCSF (US) (^{30})</td>
<td>Surgery + photon RT vs. Surgery + proton RT</td>
<td>22</td>
<td>No/No</td>
</tr>
<tr>
<td>Uterus</td>
<td>Watchful waiting vs. surgery vs. standalone photon RT vs. photon RT + proton boost RT vs. standalone proton RT</td>
<td>185</td>
<td>No/No</td>
</tr>
<tr>
<td>Prostate</td>
<td>photon RT + photon boost vs. photon RT + proton boost</td>
<td>180</td>
<td>Yes/Yes</td>
</tr>
</tbody>
</table>

GI: Gastrointestinal; IMRT: intensity modulated radiotherapy; RT: radiotherapy; SFRT: stereotactic fractionated radiotherapy; TTT: transpupillary thermotherapy
3.e. Length of followup

Followup duration varied per type of cancer. For example, in patients with glial tumors it ranged from 5 to 39 months, whereas in patients with uveal melanoma it ranged from 6 to 120 months. This partly reflects expected survival in each cancer type, as well as the different time periods over which patients with different cancers were enrolled and studied (Figure 5).

Figure 9 summarizes the mean or median followup duration for the 188 studies that reported this information. Almost all (171/188) reported a mean followup longer than 12 months and 31 reported mean followup longer than 5 years. Many studies did not report how many people were lost to followup (or were excluded due to incomplete followup).

Figure 9. Followup duration per cancer type

![Diagram showing followup duration per cancer type](image)

Gi: Gastrointestinal
The red reference lines correspond to mean followup duration of 12, 60 and 120 months.

3.f. Concurrent or prior treatments

Prior Interventions

Particle beam therapy has been explored as to both primary therapy for de novo cases and salvage therapy for relapsed and/or refractory cases. Studies on ocular melanoma, prostate cancer, non-small lung cancer, bladder cancer, breast cancer, and skin cancers mainly included untreated de novo cases without prior therapy. On the other hand, most hepatocellular cancer cases enrolled in the literature had already received prior therapeutic interventions such as
transcatheter arterial chemoembolization (TACE), percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), surgery, or photon irradiation. Studies on malignant tumors in the head, neck, and spine, some gastrointestinal cancers, bone and soft tissue sarcoma treated at least some recurrent/refractory cases (who had already failed surgery) in addition to de novo cases, chemotherapy, or conventional photon radiotherapy.

**Concurrent Interventions**

Particle beam radiotherapy has been used alone, as a localized booster therapy on top of conventional radiotherapy, or in combination with other interventions. In most studies on ocular melanoma, hepatocellular carcinoma, non-small lung cancer, and uterine cancer, treatment consisted of irradiation (particle beam or photon plus particle beam) alone. Studies on other cancers described a combination of interventions including surgery or chemotherapy. For example, most treatment strategies employed for malignant tumors in the head, neck, and spine (mainly chordoma or chondrosarcoma) and breast cancer included surgery followed by adjuvant local irradiation. Radiotherapy for prostate cancer usually accompanied neoadjuvant, concurrent, or adjuvant hormonal therapy. Bladder cancer studies adopted multi-modality therapy comprising transurethral resection of the tumor lesion followed by chemoradiotherapy. Some head and neck cancer studies and bone and soft tissue sarcoma studies also employed chemoradiotherapy depending on tumor histology.

3.g. Outcomes measured

Almost all studies reported overall survival, either as crude rates at specific followup durations (e.g., at 5 years or at the end of followup) or as time-to-event analyses (e.g., Kaplan Meier curves). A sizable fraction of these studies also reported cause specific survival. Many studies also reported rates of local control. However, the definitions of local control were heterogeneous within and across cancer types. Some defined local control anatomically (e.g., “no radiographic evidence of increase in size”); some defined it by anatomic and clinical criteria (e.g., “absence of tumor growth on followup scans and absence of clinical signs of progression”); some used broad and non-specific criteria (e.g., “absence of evidence of tumor”); and some used more detailed classification: e.g., one study defined local (“any recurrence at or adjacent to the initial primary site”) vs. regional (“any recurrence in the regional lymph nodes”) vs. metastatic (“any hematogenous recurrence”).

Most studies also reported crude rates of metastasis or distal disease. Cancer specific outcomes were also described. For example, studies on uveal melanoma reported rates of eye retention, vision retention, visual acuity and changes in tumor size, and studies on bladder cancer reported rates of bladder conservation.

3.h. Adverse events, harms, and safety issues reported

Approximately 20 percent of the studies used either the RTOG/EORTC (e.g., Hata 2007) or the LENT-SOMA scales (e.g., Hug 2002) to grade severity when reporting the harms or complications. A number of the studies made the distinction of acute vs. late complications, but “acute” and “late” were not uniformly defined across studies. A typical definition for late events was at least 3 months after the radiation treatment. Studies often
reported the number of specific harms and adverse events; however, these counts overlap, because the same patient may have experienced multiple harms. The number of patients who experienced at least one severe or serious adverse event was not routinely reported.

Most studies provided a textual description of the harms or complications. Generally, the harms/complications observed were sustained in structures (extraneous to the tumors) that were unavoidably exposed to the particle beam in the course of treatment (see Summary Table of Appendix G, where serious adverse events are summarized –less serious harms like alopecia, eye lash loss, mild dermatitis were reported in the various studies but not summarized in this table). As seen in the Summary Table (Appendix G), serious harms that can appear in the treatment of cancer with particle beam therapy (alone or with other treatments) can be debilitating, irreversible, and life threatening. However, as mentioned in the Methods it is often impossible to ascribe specific harms to (particle beam) radiotherapy rather than chemotherapy or other cointerventions.

In screening through case reports and case series of less than 10 people, we did not identify mention of an adverse event or harm that was not already listed in the studies included in the literature scan.
Discussion

Most common radiotherapy modalities use photon irradiation in the locoregional treatment of cancer. Instead, particle beam radiotherapy uses beams of protons or other charged particles such as helium, carbon or other ions. Charged particles have different depth-dose distributions compared to photons. Their physical properties allow precise targeting of the Bragg peak (and therefore the radiation dose) anywhere inside the patient’s body. The charged particle beam can be conformed to cover tumors of different shapes.

Few centers worldwide have the large and very expensive facilities to provide this treatment. Technological advances made possible the construction of smaller proton beam treatment instrumentation, and already several hospitals in the US have expressed interest to obtain it.

We relied heavily on gray literature (Internet) searches to obtain information on the number of particle beam facilities around the world, their location, instrumentation and whether they are currently active or not. The same was true for information on emerging technologies. We explored the web in a semistructured way to record information from institutional websites, and websites from organizations and companies constructing particle beam treatment facilities. However, we cannot be confident that we have obtained all existing important information, and we cannot verify the validity of the retrieved information from the various websites. Web searching was a necessary component of the methodology of the Technical Brief; relying on review articles (and published literature in general) would provide only limited or out of date information. Better methods for systematic Internet searches on new technologies have to be developed (and validated to the extent possible).

The Technical Brief focused only on studies with primary data in humans, and did not consider the large body of literature on dosimetric and simulation studies. The available slots for particle beam radiotherapy are very limited, and this may have impacted the design of studies conducted to date. The majority of studies included in the Technical Brief are noncomparative and relatively small in size. Most are retrospective and report a center’s experience in treating patients with a given cancer, so that some publications from the same centers likely refer to overlapping populations. Studies report results over long followup periods (in excess of 12 months); however it is not clear whether few people are generally lost to followup or whether people without a minimum followup duration were routinely excluded. Reported outcomes included survival (overall and cause specific) and outcomes pertaining to local and distal disease control.

Only a handful of RCTs and nonrandomized comparative studies were identified, and they compared lower vs. higher doses of particle beam therapy, particle beam therapy alone vs. other treatment, or incorporation of particle beam therapy to a treatment strategy vs. not. Studies comparing strategies that include particle beam therapy against contemporary alternatives are most informative. From that point of view, comparisons between different types of charged particle therapies should not be the only comparisons that are being evaluated (at least in most types of cancers).

In general, RCTs are needed to reliably assess the comparative efficacy (and sometimes safety) of interventions, as long as there is clinical equipoise (genuine uncertainty) over the preferred one. For certain cancers (and specific outcomes) the choice between particle beam radiotherapy and other alternatives is easy to make. For example, in patients with uveal melanomas, particle beam radiotherapy will result in higher eye retention rates compared to
surgery (which typically involves enucleation of the eye). However, for many common cancers and for many clinical outcomes there is genuine clinical equipoise. Furthermore, pathophysiological rationale, however strong, is not sufficient to choose the optimal treatment. There are numerous examples of interventions that, despite very favorable and strong pathophysiological rationale, turned out to be harmful when evaluated in RCTs.

It has been argued that for the comparison between e.g., proton and conventional radiotherapy there is no real equipoise (protons are better).60 First, the dose distributions that can be achieved with protons are in almost all cases superior to those possible with x-rays.60,61 Second, the biological effects of protons are very similar to those of photons, so the only possible differences stem from their physical properties. Third, radiation harms normal tissues as it harms malignant ones, and sparing normal tissues from radiation is self-evidently beneficial. For these reasons, there is “[verbatim] a high probability that protons can provide superior therapy to that possible with x-rays in almost all circumstances,”60 and “[verbatim] practitioners of proton beam therapy have found it ethically unacceptable to conduct RCTs comparing protons with x-rays.”60

The aforementioned line of reasoning is unsubstantiated, because it indiscriminately equates increased precision in delivering the planned radiation treatment with positive patient-relevant outcomes. This is evidently not the case when broad radiotherapy fields are indicated (e.g., whole brain radiotherapy, whole pelvis radiotherapy) to treat disease that may be locally advanced: the high precision of charged particle therapy is neither necessary nor desirable. Using a similar rationale, it is simply unknown whether precise radiation targeting can sometimes result in worse local disease control compared to conventional radiotherapy for some common cancers. Imaging limitations can underestimate the true extent of the disease and therefore mislead treatment planning; by its very nature, charged particle radiotherapy has less tolerance for inadequacies in treatment planning. (For example, there may be satellite lesions that are just distal to the fall-off of an incorrectly planned Bragg peak.) Finally, even the theorized reductions in the rate and severity of harms with particle beam therapy rather than conventional therapies have not yet been convincingly demonstrated in well-designed comparative studies.

It is not easy to decide for which cancers RCTs are necessary (and if so, for what comparisons e.g., proton radiotherapy vs. conventional radiotherapy, IMRT, or stereotactic radiosurgery). The theorized incremental clinical benefit with charged particle therapy vs. a specific type of photon based radiotherapy will vary across cancers, ranging from maximal to negligible (or even harm), and should be considered together with the corresponding incremental costs (and risks). Especially for common cancers, it is not clear where exactly along the continuum it becomes “unethical” to randomize patients.

Notwithstanding the need for RCTs, there are additional approaches that can provide potentially useful insights. Nonrandomized prospective comparative studies using proper statistical analyses that are superior to simple adjustments (such as propensity score-based analyses62 or instrumental variable regression analyses63) can be used to explore the comparative effectiveness and especially safety of charged particle therapy vs. conventional radiotherapy. Although nonrandomized designs cannot provide definitive evidence, their results may challenge conventional wisdom and formulate hypotheses for testing in randomized studies.

We clarify that there is still need for research on clinical and technical issues pertinent to particle beam therapy. Treatment protocols for charged particle therapy are constantly being refined, and the underlying complexities and considerations can differ drastically with particle type, treatment planning methodologies, cancer type and patient comorbidities. In addition, ongoing rapid technological advances in medical imaging, treatment planning and radiotherapy
delivery methodologies mandate further studies to optimize charged particle radiotherapy protocols. However, to justify any widespread use of charged particle radiotherapy to common cancers and to better appreciate the expected benefits, risks and costs it is necessary to have more comparative studies in general, and randomized trials in particular.

With newer technological advances, particle beam therapies are expected to become increasingly available (and, perhaps, at reduced cost). They will likely be used to treat patients with broader indications. This anticipated diffusion of the technology can have important implications (on economic aspects, prioritization of resources, or even on health outcomes). Especially for many patients with common cancers, such as breast, prostate, lung, and pancreatic cancers, where extreme precision in dose targeting is not a sine-qua-non, it is essential that the theorized advantages of particle beam therapy vs. contemporary alternative interventions are first proven in controlled clinical trials. Concomitant economic evaluations would probably prove useful in informing cost-effectiveness or other economic analyses.

It is likely that focused systematic reviews will not be able to provide a definitive answer on the effectiveness and safety of charged particle beam radiotherapies compared to alternative interventions. This is largely because of the relative lack of comparative studies in general, and randomized trials in particular. For example, a recent Effective Health Care (EHC) report that included a systematic review on the comparative effectiveness and harms of treatments for clinically localized prostate cancer did not provide a definitive conclusion on the role of proton beam radiotherapy.

**Conclusion**

In brief, there are many publications on particle (mainly proton) beam therapy for the treatment of cancer. However, they typically do not use a concurrent control, focus on heterogeneous populations, and employ different definitions for outcomes and harms. Comparative studies in general, and randomized trials in particular, are likely needed to document the theorized incremental advantages of particle beam therapy over other radiotherapies (e.g., IMRT, conventional radiotherapy or stereotactic photon radiosurgery) in many cancers. In addition, incremental benefits should be considered and interpreted with respect to corresponding incremental costs (and risks). This is especially important in the light of the anticipated diffusion of this technology to treating common cancers in which extreme precision in radiation delivery is not a sine-qua-non. We anticipate that systematic reviews of the current literature will not be able to provide definitive answers on the effectiveness and safety of particle beam therapy compared to other interventions for most if not all cancer categories.
References


